The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy. (2022)

First Author: Thompson NA
Attributed to:  The Genomic Atlas of Dermatological Tumours (DERMATLAS) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1186/s12885-021-09156-x

PubMed Identifier: 35073853

Publication URI: http://europepmc.org/abstract/MED/35073853

Type: Journal Article/Review

Volume: 22

Parent Publication: BMC cancer

Issue: 1

ISSN: 1471-2407